Stemline Therapeutics, Inc. (NASDAQ:STML)‘s stock had its “buy” rating restated by Cowen and Company in a research report issued on Tuesday, October 31st.
STML has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Stemline Therapeutics in a report on Tuesday, September 12th. ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $33.40.
Shares of Stemline Therapeutics (STML) traded down $0.05 during midday trading on Tuesday, reaching $14.00. 229,280 shares of the company’s stock were exchanged, compared to its average volume of 436,329. Stemline Therapeutics has a 1 year low of $5.50 and a 1 year high of $14.60.
TRADEMARK VIOLATION NOTICE: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/stemline-therapeutics-stml-buy-rating-reiterated-at-cowen-and-company/1746661.html.
Hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC acquired a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at $102,000. Nationwide Fund Advisors lifted its stake in shares of Stemline Therapeutics by 7.8% in the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 858 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Stemline Therapeutics by 3.8% in the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 500 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at $147,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares during the last quarter. 46.54% of the stock is owned by institutional investors and hedge funds.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.